Is Novo Nordisk helping Americans save taxpayer money or ripping them off? The company’s CEO is scheduled to testify Tuesday ...

Wegovy is a once-weekly injection approved by the U.S. Food and Drug Administration (FDA) to treat obesity in people 12 and ...

Semaglutide, the underlying drug marketed as Ozempic and Wegovy, works by mimicking a hormone that triggers the body to feel ...

Sima Sistani, who took up the CEO post at WW International two-and-a-half years ago, is out, according to the company.

U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North ...

Weight loss surgeries, GLP-1 drugs such as Wegovy, and lifestyle changes may all be able to boost brain health, though research varies. Most people know that obesity is linked to chronic disease and ...

Novo Nordisk has seen strong demand for its semaglutide products for weight loss. Its patent for Wegovy is not set to expire until 2032. The Danish company says it is working to boost its ...

Our editors also may be in touch with follow-up questions. Due to a Wegovy shortage coupled with Ozempic’s weight loss effects going viral on social media, people without type 2 diabetes have ...

Wegovy, Zepbound and other cutting-edge weight-loss drugs can be tough to get these days. They're in short supply, and often too expensive to afford without insurance coverage. Advertisement ...

Results from a new study showed people taking Wegovy (semaglutide) for weight loss were 33 percent less likely to die of COVID-19 than people taking placebo. They were also 15 percent less likely ...

Novo Nordisk A/S (NYSE:NVO) will consider ways to help patients get affordable prescriptions for weight loss drugs, CEO Lars ...

showed faster weight loss than its blockbuster weekly injection for chronic weight management, Wegovy (semaglutide), in the phase I study. Per the data, patients receiving the highest dose of ...